Portal de Periódicos da CAPES

The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials

2018; Taylor & Francis; Volume: 14; Issue: 9 Linguagem: Inglês

10.1080/21645515.2018.1473698

2164-554X

Ellen L. Suder, Wakako Furuyama, Heinz Feldmann, Andrea Marzi, Emmie de Wit,

COVID-19 epidemiological studies

The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the progress of several vaccines and antivirals through clinical trials, including the replication-competent vesicular stomatitis virus-based vaccine expressing the EBOV glycoprotein (VSV-EBOV). Extensive preclinical testing in animal models demonstrated the prophylactic and post-exposure efficacy of this vaccine, identified the mechanism of protection, and suggested it was safe for human use. Based on these data, VSV-EBOV was extensively tested in phase 1–3 clinical trials in North America, Europe and Africa. Although some side effects of vaccination were observed, these clinical trials showed that the VSV-EBOV was safe and immunogenic in humans. Moreover, the data supported the use of VSV-EBOV as an emergency vaccine in individuals at risk for Ebola virus disease. In this review, we summarize the results of the extensive preclinical and clinical testing of the VSV-EBOV vaccine.